Meca-Lallana V - Search Results

1

Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?

Aguirre C, Meca-Lallana V, Barrios-Blandino A, Del Río B, Vivancos J. Aguirre C, et al. Mult Scler Relat Disord. 2020 Sep;44:102250. doi: 10.1016/j.msard.2020.102250. Epub 2020 Jun 3. Mult Scler Relat Disord. 2020. PMID: 32531754 Free PMC article.

2

[CLIPPERS syndrome with atypical distribution of lesions in magnetic resonance imaging of the brain].

Canneti B, Mosqueira AJ, Gilo F, Carreras T, Barbosa A, Meca-Lallana V, Vivancos J. Canneti B, et al. Rev Neurol. 2013 Oct 16;57(8):354-8. Rev Neurol. 2013. PMID: 24081890 Free article. Spanish.

3

Tumefactive demyelinating lesions of 15 patients: Clinico-radiological features, management and review of the literature.

Sánchez P, Meca-Lallana V, Barbosa A, Manzanares R, Palmí I, Vivancos J. Sánchez P, et al. J Neurol Sci. 2017 Oct 15;381:32-38. doi: 10.1016/j.jns.2017.08.005. Epub 2017 Aug 12. J Neurol Sci. 2017. PMID: 28991707 Review.

4

Tumefactive multiple sclerosis lesions associated with fingolimod treatment: Report of 5 cases.

Sánchez P, Meca-Lallana V, Vivancos J. Sánchez P, et al. Mult Scler Relat Disord. 2018 Oct;25:95-98. doi: 10.1016/j.msard.2018.07.001. Epub 2018 Jul 19. Mult Scler Relat Disord. 2018. PMID: 30056362

5

Cytomegalovirus primary infection in a patient with multiple sclerosis treated with alemtuzumab.

Aguirre C, Meca-Lallana V, Sánchez P, Vivancos J. Aguirre C, et al. Mult Scler Relat Disord. 2019 Oct;35:270-271. doi: 10.1016/j.msard.2019.07.026. Epub 2019 Aug 6. Mult Scler Relat Disord. 2019. PMID: 31442904

6

Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study.

Meca-Lallana J, Ayuso T, Martínez-Yelamos S, Durán C, Contreras Martín Y, Herrera Navarro N, Pérez Sempere A, Álvarez-Cermeño JC, Millán Pascual J, Meca-Lallana V, Romero Sevilla R, Ricart J. Meca-Lallana J, et al. Eur Neurol. 2020;83(1):25-33. doi: 10.1159/000505778. Epub 2020 Mar 18. Eur Neurol. 2020. PMID: 32187609 Free PMC article.

7

[EMCAM (Multiple Sclerosis Autonomous Community of Madrid) document for the management of patients with multiple sclerosis during the SARS-CoV-2 pandemic].

Costa-Frossard L, Moreno-Torres I, Meca-Lallana V, García-Domínguez JM, En Representación Del Grupo de Estudio de Enfermedades Desmielinizantes de la Comunidad Autónoma de Madrid ERDGEEDCAM. Costa-Frossard L, et al. Rev Neurol. 2020 May 1;70(9):329-340. doi: 10.33588/rn.7009.2020155. Rev Neurol. 2020. PMID: 32329046 Free article. Review. Spanish.

8

Establishment of a safety protocol for the administration of treatments in multiple sclerosis during the SARS-CoV-2 pandemic.

Meca-Lallana V, Aguirre C, Cardeñoso L, Alarcon T, Figuerola-Tejerina A, Del Río B, Álvarez MR, Vivancos J. Meca-Lallana V, et al. Mult Scler Relat Disord. 2020 Sep;44:102244. doi: 10.1016/j.msard.2020.102244. Epub 2020 Jun 2. Mult Scler Relat Disord. 2020. PMID: 32544863 Free PMC article. No abstract available.

9

COVID-19 will change MS care forever - Yes.

Meca-Lallana V. Meca-Lallana V. Mult Scler. 2020 Sep;26(10):1147-1148. doi: 10.1177/1352458520932767. Epub 2020 Jun 22. Mult Scler. 2020. PMID: 32567486 No abstract available.

10

COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies.

Meca-Lallana V, Aguirre C, Beatrizdel Río, Cardeñoso L, Alarcon T, Vivancos J. Meca-Lallana V, et al. Mult Scler Relat Disord. 2020 Sep;44:102306. doi: 10.1016/j.msard.2020.102306. Epub 2020 Jun 15. Mult Scler Relat Disord. 2020. PMID: 32585617 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

60 results

Search Page